Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Up 512.5% in February

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 147 shares, an increase of 512.5% from the February 12th total of 24 shares. Based on an average trading volume of 1,434 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 1,434 shares, the short-interest ratio is presently 0.1 days.

Ascentage Pharma Group International Trading Up 3.4%

Shares of Ascentage Pharma Group International stock opened at $24.49 on Wednesday. The business has a 50 day simple moving average of $25.17 and a two-hundred day simple moving average of $31.41. Ascentage Pharma Group International has a 12 month low of $17.56 and a 12 month high of $48.45. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors and hedge funds have recently bought and sold shares of AAPG. Mirae Asset Global Investments Co. Ltd. purchased a new position in Ascentage Pharma Group International during the 3rd quarter valued at about $96,000. ABC Arbitrage SA purchased a new stake in Ascentage Pharma Group International during the 3rd quarter worth approximately $204,000. Citadel Advisors LLC purchased a new stake in shares of Ascentage Pharma Group International during the third quarter worth $383,000. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter valued at $391,000. Finally, UBS Group AG boosted its holdings in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares during the period.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on AAPG shares. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research note on Monday, November 24th. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a research report on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Oppenheimer began coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They set an “outperform” rating and a $45.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $48.40.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.